Suchen
Pfizer Inc
PFEZur Watchlist hinzufügen
24.480USD
+0.310+1.28%
Handelsschluss 07/13, 16:00（ET）Kurse um 15 Minuten verzögert
139.52BMarktkapitalisierung
18.59KGV TTM
mehr Informationen über Pfizer Inc Unternehmen
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Pfizer Inc Informationen
BörsenkürzelPFE
Name des UnternehmensPfizer Inc
IPO-datumFeb 22, 2080
CEOBourla (Albert)
Anzahl der mitarbeiter81000
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 22
Addresse66 Hudson Boulevard East
StadtNEW YORK
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl10001-2192
Telefon12127332323
Websitehttps://www.pfizer.com/
BörsenkürzelPFE
IPO-datumFeb 22, 2080
CEOBourla (Albert)
Führungskräfte von Pfizer Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
394.63K
+4.08%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
165.26K
+2.36%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+7.61%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
68.47K
-3.36%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
32.73K
+5.39%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
--
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
--
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
26.59K
+6.54%
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
394.63K
+4.08%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
165.26K
+2.36%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+7.61%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
68.47K
-3.36%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
32.73K
+5.39%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Pfizer Inc?
Die fünf größten Anteilseigner von Pfizer Inc sind: Dr. Albert Bourla, Ph.D.
Wie viele Institutionen halten Anteile an Pfizer Inc (PFE)?
Mit Stand vom 2026Q1 halten 4824 Institutionen Anteile an Pfizer Inc, mit einem Gesamtmarktwert von etwa 3.98B, was 69.87% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 29483336.00 gestiegen.
Was ist die größte Einnahmequelle von Pfizer Inc?
Am 2026Q1 erzielte das Geschäft mit Eliquis alliance revenues and direct sales für Pfizer Inc den höchsten Umsatz in Höhe von 7.96B, was 12.72% des Gesamtumsatzes entspricht.